Compare AGEN & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | TMCI |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | 450 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 292.0M |
| IPO Year | 1999 | 2021 |
| Metric | AGEN | TMCI |
|---|---|---|
| Price | $7.85 | $4.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.50 | $4.77 |
| AVG Volume (30 Days) | ★ 873.0K | 217.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | $42,877,086.00 | ★ $212,690,000.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ 89.95 | 1.59 |
| 52 Week Low | $2.71 | $1.17 |
| 52 Week High | $8.85 | $7.10 |
| Indicator | AGEN | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 51.42 |
| Support Level | $2.97 | $4.28 |
| Resistance Level | $8.64 | $4.86 |
| Average True Range (ATR) | 0.43 | 0.20 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 54.07 | 50.00 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.